PolyNovo Limited (ASX:PNV): What Do FY26 Results Reveal About NovoSorb Sales and Manufacturing Expansion?

Aditi Sarkar

27 October 2026 10:33 PM AEDT

PolyNovo Limited (ASX:PNV): What Do FY26 Results Reveal About NovoSorb Sales and Manufacturing Expansion?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

PolyNovo Limited (ASX:PNV) reported FY26 total revenue of AUD 150.0 million, an increase of 16.1% YoY.
Commercial product sales increased 16.7% YoY to AUD 138.4 million.
FY26 EBITDA reached AUD 12.1 million, while statutory NPAT was AUD 7.3 million.
Operating cash flow totalled AUD 23.1 million; the new manufacturing facility entered validation.

PolyNovo Limited develops and supplies medical devices for managing burns and complex wounds using its NovoSorb polymer technology. Following the release of its FY26 financial results and September annual report, PolyNovo Limited (ASX:PNV) shares closed at AUD 0.87 on 27 October 2026. The business reported increased commercial product sales and positive operating cash flow during the financial year, while advancing manufacturing capacity and work relating to additional regulatory indications. These developments sit alongside a reduction in reported net profit and the company’s continuing investment in expanding clinical and commercial applications.

Company Business

PolyNovo Limited (ASX:PNV) develops, manufactures and commercialises medical devices based on its biodegradable NovoSorb polymer platform. Its principal products include NovoSorb Biodegradable Temporizing Matrix (BTM), used in the management of burns and complex wounds, and NovoSorb MTX, intended for use in single-stage wound reconstruction procedures. Product utilisation depends on clinical requirements, product approvals, hospital purchasing arrangements and clinician adoption.

The company is headquartered in Melbourne and serves customers in the United States, Australia, Europe and other international markets, using direct commercial operations and distribution arrangements. Manufacturing is centred in Port Melbourne. Expansion of international sales requires coordination across regulatory processes, clinical education, supply chains and product quality systems. PolyNovo Limited (ASX:PNV) also evaluates other potential uses of its polymer technology, although commercialisation decisions remain subject to development and regulatory assessments.

Recent Development

In August 2026, PolyNovo released its full-year results for the 12 months ended 30 June 2026. Commercial product sales increased in both the United States and markets outside the United States. The company reported US-market product sales growth of 15.6% in Australian-dollar terms and a 20.0% increase in rest-of-world commercial sales. Currency movements affected reported growth rates: on a constant-currency basis, the respective increases were 21.1% and 21.9%.

The FY26 results also detailed progress in the commercial rollout of NovoSorb MTX and development activity supporting wider applications of NovoSorb BTM. Management outlined continued work on a US premarket approval submission concerning a full-thickness burns indication. A planned regulatory submission does not itself establish approval, timing or future revenue.

Construction of the new Port Melbourne manufacturing facility was completed during FY26, with validation work progressing before a planned operational transition in FY27. In September, the company released its annual report and announced appointments to its board. An October announcement also disclosed the planned departure of its chief financial officer, Jan Gielen. PolyNovo’s annual general meeting is scheduled for 29 October 2026.

Financial Performance and Sector Context

PolyNovo Limited (ASX:PNV) reported FY26 total revenue, including other income, of AUD 150.0 million versus AUD 129.2 million in FY25, representing growth of 16.1% YoY. Commercial sales increased to AUD 138.4 million from AUD 118.6 million, a 16.7% YoY rise. Revenue under its BARDA arrangement declined to AUD 5.3 million from AUD 8.6 million as associated trial activities progressed. The combination of product sales, research-related funding and other income matters when comparing headline revenue with underlying commercial activity.

Reported EBITDA increased 8.1% YoY to AUD 12.1 million from AUD 11.2 million. Statutory net profit after tax declined to AUD 7.3 million from AUD 13.2 million, reflecting a comparison affected by the prior year’s income tax benefit, among other items. Gross margin declined to 89.0% from 95.6%. The company reported AUD 23.1 million in operating cash flow and AUD 9.4 million in free cash flow for FY26, alongside cash and cash equivalents of AUD 35.4 million at 30 June 2026.

Manufacturing capital expenditure formed an important part of the investment programme, including work to complete the additional Port Melbourne facility. In the medical-device sector, revenue development is tied to clinical evidence, regulatory status, reimbursement arrangements and hospitals’ adoption of devices. These factors can differ by jurisdiction and clinical indication, making geographic sales mix and product-level disclosures relevant to the company’s operating performance.

Risks to Consider

PolyNovo Limited (ASX:PNV) faces regulatory and reimbursement uncertainty for proposed additional indications, as well as clinical adoption and competitive risks. Manufacturing expansion creates validation, quality-control and utilisation requirements. Gross-margin movements and operating expenditure may affect profitability as production and sales volumes change. International operations introduce currency exposure and regional differences in purchasing arrangements. Research programmes may require expenditure without resulting in an approved or commercially adopted product.

What to Watch Next

The 29 October annual general meeting may provide an opportunity for further management commentary, although any new disclosures should be assessed when released. For PolyNovo Limited (ASX:PNV), subsequent financial updates can clarify the pace of NovoSorb BTM and MTX sales, divisional geographic mix, cash conversion and production efficiency. Other milestones include validation of the expanded manufacturing facility, progress on the US regulatory submission and information about reimbursement access. Investors can also monitor the transition in the finance leadership role and any formally announced changes in strategy or guidance.

Key Insights

PolyNovo Limited (ASX:PNV) delivered higher FY26 commercial sales, revenue and operating cash flow, while statutory net profit declined. Its expanded manufacturing footprint, emerging product applications and regulatory work add execution requirements to its existing wound-care business. The next disclosures will help establish how sales growth, operating costs and factory utilisation develop during FY27, without implying a particular share-price outcome.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.